Saxena S N, Bhau L N, Singh G, Gowal D, Sood Y K, Misra C N, Das B K
Indian J Med Res. 1989 Nov;89:362-7.
The immune status of 40 volunteers who received the full course of Japanese encephalitis (JE) vaccine a year earlier and 15 individuals who had received only a booster dose at the same time, was studied by estimating the level of persistence of protective antibody in the sera. All the sera showed persistence of 100 per cent seroconversion rate. Individuals who had the full course of vaccination still had high levels of antibody (mean 2.8 Iog10); however there was a fall of 0.8 Iog10 from the post-booster level. Volunteers who had received only a booster dose, also showed persistence of high level of protective antibody (mean 2.4 Iog10), a drop of 0.9 Iog10 from the post-booster level. Neutralizing (N) antibody estimated using Dibrugarh (7812474) strain of JE virus also demonstrated persistence of high level of protective antibody against this virus (mean 2.4 Iog10). Persistence of high level of protective antibody against homologus and heterologus (Dibrugarh) virus strains and absence of vaccine related side-effects even one year after administration of JE vaccine produced in India, demonstrates the immunizing potency and safety of this new vaccine.
通过评估血清中保护性抗体的持续水平，对40名一年前接种了日本脑炎（乙脑）疫苗全程的志愿者和15名同时仅接种了一剂加强针的个体的免疫状况进行了研究。所有血清的血清转化率均持续保持在100%。接种了疫苗全程的个体仍具有高水平的抗体（平均2.8 log10）；然而，与加强针接种后的水平相比下降了0.8 log10。仅接种了一剂加强针的志愿者也显示出高水平的保护性抗体持续存在（平均2.4 log10），比加强针接种后的水平下降了0.9 log10。使用乙脑病毒迪布鲁格尔（7812474）株评估的中和（N）抗体也表明针对该病毒的高水平保护性抗体持续存在（平均2.4 log10）。在接种印度生产的乙脑疫苗一年后，针对同源和异源（迪布鲁格尔）病毒株的高水平保护性抗体持续存在，且未出现疫苗相关副作用，证明了这种新疫苗的免疫效力和安全性。
